InnoSIGN Bio is a verified, high-potential biotechnology spin-off from Philips (founded 2021) specializing in mRNA-based pathway activity profiling (OncoSIGNal) for precision oncology. The company has raised over $20M in funding (Series A) and operates a CLIA laboratory in the US. However, the project submission itself was of extremely poor quality, containing hallucinated claims (e.g., 'most people have used my product', 'audience: everyone') and unprofessional details ('ThunderHunter'). The high score reflects the verifiable reality of the entity's significant technological value and market position, heavily penalized by the 'Response Quality' and 'Audience Reach' metrics due to the inaccuracies in the submission text.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline